FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Affimed N.V Announces Positive Initial Clinical Data”
Affimed N.V. (NASDAQ: AFMD) surged over 30% in premarket trading after the company announced positive initial clinical data from an investigator-sponsored study at The University of Texas MD Anderson Cancer Center.
The study evaluated cord blood-derived natural killer cells pre-complexed with Affimed’s innate cell engager and all four patients experienced significant disease reduction, with two complete responses and two partial responses as assessed by the investigator, with an objective response rate of 100%.
Affimed is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager (ICE®) molecules, which use patients’ immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE®.
For more information, please visit: Affimed N.V.
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.